New IBS Biomarker

Goal Statement

This activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the management of FGIMDs.

Target Audience

The CME/CE meeting series will target gastroenterologists, nurse practitioners, physician assistants, and allied health care professionals managing patients with FGIMDs.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Discuss evidence linking acute gastroenteritis and altered intestinal microbiota to IBS pathogenesis

Describe the rationale for the use of emerging biomarkers in IBS diagnosis

Discuss potential diagnostic and prognostic roles for emerging IBS biomarkers

Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the GI Health Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-15-050-H04-P. This program is designated for up to 0.25 contact hours (0.25 CEUs) of continuing pharmacy education credit.

Release Date: January 20, 2016
Expiration Date: January 20, 2017   
*This program has expired. CME credit is no longer available.

Disclosure

All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relationships to disclose.

Learner Assurance Statement

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Supported by an educational grants from Commonwealth Laboratories, Inc., Prometheus Laboratories, QOL Medical Laboratories, Inc., Salix Pharmaceuticals, Inc., Takeda Pharmaceuticals International, Inc., U.S. Region and Sucampo.